Cephalon (company)
American biopharmaceutical company
Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company. Baldino served as Cephalon's chairman and chief executive officer, until his death in December 2010. The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.
As noted by fundinguniverse.com:
Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006. Sales revenues reached $2.8 billion in 2010, ranking Cephalon among the leading biopharmaceutical companies in the world at that time.
On May 2, 2011, Teva Pharmaceutical Industries announced it would acquire Cephalon.
This brief starts where responsible research should: with the source description of “Cephalon (company)” as american biopharmaceutical company. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the history & society register because the source frames it as american biopharmaceutical company. Its deeper value depends on whether names, dates, institutions and citations support that framing.
The record creator and administrative purpose are central evidence, because official documentation reflects both action and institutional priorities. The source revision retrieved here is dated Sep 22, 2026. The linked authority identifier is Q15427523. 1 of 1 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 1987, 2010, 1000 and 2006.
Official terminology may obscure informal participation, dissent or communities documented only indirectly. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Cephalon (company)”, its source revision and the description used here.
- Expand the search: follow Cephalon (company) primary sources, Cephalon (company) archive and Cephalon research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Cephalon (company)”?
- Who created the surviving record, and for what administrative purpose?
- Which voices are present, absent or mediated by the institution?
Search terms from this dossier
This entry incorporates text from “Cephalon (company)” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.